Wall Street ends 2026 positively with tech stocks dominating, but concerns over valuations drive interest in smaller AI ...

Summary In this episode of The Defenders Log, Paul Mockapetris, the architect of DNS, discusses the evolving role of the Domain Name System from a simple directory to a sophisticated security tool. He ...

The new major version with a new JIT compiler, a revised parallelization API, and a maturing type system paves the way for ...

Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

The key to solving many apparently separate relationship problems is to explore what they have in common. Analyzing those ...